Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for ELTP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 10.07M
March 31, 2026 9.146M
December 31, 2025 -5.278M
September 30, 2025 5.104M
June 30, 2025 14.78M
March 31, 2025 3.918M
December 31, 2024 -1.064M
September 30, 2024 1.457M
June 30, 2024 3.144M
March 31, 2024 2.06M
December 31, 2023 -2.396M
September 30, 2023 -0.2359M
June 30, 2023 -2.710M
March 31, 2023 2.969M
December 31, 2022 -0.5679M
September 30, 2022 1.495M
June 30, 2022 -0.5575M
March 31, 2022 1.605M
December 31, 2021 3.034M
September 30, 2021 0.1538M
June 30, 2021 1.716M
March 31, 2021 -0.7494M
December 31, 2020 1.235M
September 30, 2020 1.900M
June 30, 2020 0.8074M
Date Value
March 31, 2020 -1.206M
December 31, 2019 -0.3122M
September 30, 2019 -0.4638M
June 30, 2019 0.1883M
March 31, 2019 -2.136M
December 31, 2018 -1.268M
September 30, 2018 -1.679M
June 30, 2018 -1.710M
March 31, 2018 -1.014M
December 31, 2017 -0.4781M
September 30, 2017 -2.226M
June 30, 2017 -1.091M
March 31, 2017 -4.076M
December 31, 2016 -0.7264M
September 30, 2016 -2.317M
June 30, 2016 -0.7642M
March 31, 2016 0.6064M
December 31, 2015 -1.784M
September 30, 2015 -3.479M
June 30, 2015 1.891M
March 31, 2015 -3.856M
December 31, 2014 -2.606M
September 30, 2014 -4.428M
June 30, 2014 -4.213M
March 31, 2014 -1.420M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Nektar Therapeutics -75.77M
Daré Bioscience, Inc. -6.775M
Eton Pharmaceuticals, Inc. 7.255M
ANI Pharmaceuticals, Inc. 56.67M
Corcept Therapeutics, Inc. 33.54M